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H mid-1 970s by Kohler and Milstein,' made it possible to produce virtually limitless quantities of highly specific monoclonal antibodies (MoAbs) that recognize distinct epitopes of cellular antigens. This advance, combined with molecular probes that identify antigen-receptor gene rearrangements, has led to valuable insights into normal lymphocyte differentiation and the cellular origins of lymphoid leukemia.2 Improved methods of immunologic marker evaluation have also increased the precision of diagnosis and classification of the lymphoid malignancies, now permitting the detection of minimal residual di~ease.~,~ Most recently, the study of chromosomal abnormalities specific for the major immunologic subtypes of leukemia has pinpointed genes with pivotal roles in cell transformation:
In this review, we summarize the key aspects of normal Band T-cell ontogeny as it relates to the diagnosis and classification of acute lymphoblastic leukemia (ALL). We also address the critical issue of clinical relevance of immunologic marker evaluation in ALL and briefly compare the immunophenotypic findings between childhood and adult ALL. Because most of the differentiation antigens found on B or T lymphocytes have also been identified on other cell types, we use the term lineage-associated, rather than lineage-specific, throughout this article.
DEVELOPMENT OF LYMPHOID CELLS
Lymphocytes derive from pluripotent stem cells that also give rise to erythroid, megakaryocytic, and myeloid cells. Whether T and B lymphocytes originate from a common stem cell committed to the lymphoid developmental pathway is not known. Commitment to either the B-or T-cell lineage occurs as progenitor cells enter the primary organs of lymphocyte differentiation, ie, the bone marrow for B cells and the thymus for T cells. At the cellular level, the proliferation and differentiation of lymphoid progenitors is driven by the microenvironment provided by these primary organs. In the bone marrow, this milieu, generally referred to as stroma, includes adventitial cells, reticular cells, endothelial cells, fibroblasts, macrophages, adipocytes, and an extracellular matrix. Stromal cells produce a variety of cytokines that are required for the differentiation and proliferation of B-lymphoid cell^.^,^ In the thymus, a highly specialized network of epithelial cells, dendritic cells and macrophages is essential for T-cell clonal expansion and selection.
Generation of Immunologic Diversity
The diverse repertoire of antigen specificities afforded by Igs and T-cell receptors for antigen (TCR) is generated by successive rearrangements of the genes encoding these protein~.~.' Diversity is enhanced by random addition of nucleotides to the junctional regions of Ig loci in B cells or the TCR genes in T When these rearrangements are productive (ie, result in an open reading frame for transcription of mRNA followed by translation to produce the protein components of Ig or TCR), they promote further diversity through random association of different heavy and light Ig chains in B cells and different TCR chains in T cell^.^^' An ordered sequence of gene rearrangement, shown in Figs 1 and 2, has been postulated for normal B-and T-cell ontogeny. Ig and TCR gene rearrangements have also served as clonal markers of leukemia, to the extent that specific patterns of rearrangement have been incorporated into some leukemia classification schemes?-I2
Cell Markers
Besides the proteins encoded by Ig and TCR genes, lymphoid cells sequentially express an array of other lineage-related cellular antigens during their normal maturation (Figs 1 and 2). The list of lymphoid differentiation antigens and the MoAbs that recognize them has grown rapidly. Since 1982, four international workshops have been held with the sole purpose of reaching a consensus on the nomenclature and specificity of these molecules. At the fourth workshop (Vienna, Austria, 1989), 35 new cluster of differentiation (CD) groups and subgroups were added, and seven previously established groups were redefined.13 Altogether, 89 CD groups and subgroups (CDla to CD,78) were designated. Table 1 lists some of the properties and functions of the cellular differentiation antigens commonly recognized in immunologic marker studies of the acute leukemias. Only questions pertinent to the lymphoid-associated antigens will be addressed here; the reader is referred to a recent review for information on myeloid cells.14 More than 20 differentiation antigens have been identified on B-lineage cells." Their order of expression during cell maturation has been the subject of intense study using panels of lineage-associated MoAbs. Evidently, CD 19 and cytoplasmic CD22 appear earliest during B-cell ontogeny and are expressed in virtually all cases of B-lineage
The remainder of the temporal se-quence can be summarized as CD24 + CDlO + CD20 + CD22 + cytoplasmic Ig (clg) + CD2 1 + surface Ig (sIg) + CD23 (Fig 1) . According to the consensus hierarchy of Ig gene rearrangement during B-cell ontogeny, the assembly of Ig heavy-chain genes precedes the assembly of K light-chain genes, which in turn precedes that of X light-chain genes.18-20 In contrast to heavy-chain gene rearrangements, light-chain gene rearrangements appear restricted to B cells, with only a few exception^.^'-^^ Studies of antigen expression16,2"28 and Ig gene rearrangein B-lineage ALL have led to different models of leukemic B-cell development. Nadler et alZ4 proposed discrete stages of neoplastic and normal B-lineage differentiation based on the expression of HLA-DR, CDIO, CD19, ment18-20 .
T-cell Ontogeny
and CD20 molecules. greave^^'^^^ originally postulated that leukemic lymphoblasts are the neoplastic counterparts of normal lymphopoietic progenitors "frozen" at various stages of development. Others15,16,26,3G32 subsequently documented the existence of occasional lymphoid cells whose phenotypic features were similar to those proposed by Greaves. Leukemic clones lose their ability to differentiate but retain their proliferative p~t e n t i a l .~~.~~ In this regard, the majority of B-lineage leukemic lymphoblasts have nonproductive Ig gene rearrangements, consistent with their inability to develop n~rmally.'~ Borella and Sen33.34 first identified T lymphoblasts by the ability of these cells to form rosettes with sheep erythrocytes (E-rosettes). Subsequent studies showed that heteroantisera raised against thymocytes reacted not only with blasts from E-rosette-positive leukemias but also with those from other T-cell leukemia cases.35 Indeed, it has since been recognized that nearly one-half of T-cell cases do not form E-r~settes.~~,~' In the past decade, the discovery of TCR genes3843 and the wider availability of MoAbs to Tcell-associated antigens" have stimulated remarkable progress in understanding the ontogeny of T lymphocytes.
Similar to Ig genes, TCR genes rearrange during T-cell differentiation to permit receptor expression and diver~i t y .~~ Two different types of TCR molecules have been identified on T cells; both consist of a polymorphic heterodimer of two glycosylated polypeptide chains (a@ or 76) and a monomorphic glycoprotein complex (CD3). Extensive analysis of TCR expression during development has shown that, although TCR genes are frequently rearranged in Blineage ALL, such changes are usually n o n p r o d u~t i v e .~~~~~'~~ Traditionally, T cells have been classified according to changes in the expression of surface differentiation antigens (Fig 2) . Reinherz et a P 7 proposed a three-stage scheme of thymic maturation, which has provided a framework for the classification of T-cell ALL. However, there are exceptions to this model for both normal thymocytes and leukemic cells, suggesting a continuum of phenotypic changes (rather T-cell lineage. Lineage-independent markers. Several CD antigens not related to a specific cell lineage are routinely measured on leukemic cells (Table 1) . CDlO, the common ALL antigen, was among the first differentiation antigens used to subclassify acute lymphoid leukemia. Initially described in 1975 (Greaves et a162), this 100-Kd glycoprotein was later identified as the membrane-associated enzyme neutral endopep t i d a~e ,~~,~~ which cleaves peptides at the amino terminus of hydrophobic r e~i d u e s .~~.~~ Its presence on leukemic cells was originally taken as a marker of common ALL,67-69 whereas its absence in 5% to 15% of non-T, non-B cases was used to recognize ALL variously termed null cell, unclassified, or ~n d i f f e r e n t i a t e d .~~~~ More recent studies have shown CD 10 expression on leukemic cells of both the T and B lineages and on some nonhemopoietic cells as we11.68,75-77 The role of the antigen in leukemic cell proliferation and differentiation remains uncertain.
The CD34 antigen, a molecule of 115 Kd mass, is expressed selectively by primitive myeloid and lymphoid progenitor ~e l l s .~~-~~ The 28-kb gene encoding this protein was recently cloned and its genomic DNA sequence was characterized,81.82 but the function of the product has not been defined. In a Pediatric Oncology Group study of 795 children with non-T, non-B ALL, CD34 expression was detected in 74% of the cases.83 CD34+ blast cells were more likely to coexpress CD22, CD9, and CD13 antigens, but less likely to coexpress cIg. From a study of a limited number of cases, CD34 antigen expression was suggested to occur more often in non-T, non-B ALL than in T-cell CD45, the leukocyte common antigen, is found on all hematopoietic cells except erythrocytes and platelets, and is absent from nonhematopoietic tissues.86 CD45 antigens belong to a family of cell surface glycoproteins with a heavily glycosylated extracellular domain, a transmembrane segment, and a large cytoplasmic domain that has tyrosine phosphatase a~t i v i t y .~~,~~ The CD45 molecule appears in at least four discrete forms that differ in their carbohydrate and protein backbone structure^.^^*^^ Several studies suggest that CD45 may be involved in the regulation of hematopoietic cell growth, differentiation, and cell a c t i v a t i~n .~~*~~ Despite the ubiquitous expression of this antigen on normal leukocytes and their precursors, it may be absent from some cases of acute leukemia or from some leukemic cell
In our recent study of 249 childhood ALL cases, CD45 expression was undetectable or vanishingly low on lymphoblasts from 32 patients (1 3%), all of whom had Blineage ALL.93 The percentage of blast cells expressing this antigen was higher in T-cell than in B-lineage cases. There appeared to be an inverse relationship between CD45 expression and that of the CD20 and CD34 antigens. This finding paralleled the association seen during normal B-cell development, except for an increase in CD20 positivity while CD45 expression declined.9s95
CD38 (the plasma cell activation antigen) and CD7 1 (the T-cell activation antigen) are integral membrane glycoproteins appearing at the earliest stages of thymocyte maturat i~n .~~.~~'~ CD38 is expressed by about 20% of normal bone marrow cells, mitogen-activated peripheral T lymphocytes and plasmacytes, and blast cells of the acute lymphoid and myeloid leukemias, but is absent on virtually all resting T lymphocyte^.^^.^^.^^ Despite its wide expression, the precise function of CD38 is not known. Among CD34' human progenitor cells, the expression of CD38 has been correlated with lineage commitment (CD38-cells are not committed to a particular lineage and are capable of extensive self-renewal)."' Recently, from observations of HLA-DR expression, Huang and Terstappenlo2 further subdivided the CD34' CD38-pluripotent stem cells from human fetal bone marrow into two distinct subsets. The HLA-DR+ subset can differentiate into cells of all hematopoietic lineages and the HLA-DR-subset into hematopoietic precursors and stromal cells capable of supporting their differentiation. CD7 1 is generally expressed more strongly by proliferating or transformed cells than by resting cells because of its role in iron ~p t a k e .~~,~~ The antigen has been detected on dividing cells of all hematopoietic lines and on malignant lymphoid and myeloid cells.57.97,98 In a recent study by our group, all 62 T-cell ALL cases and 238 of 263 B-lineage ALL cases expressed CD38.1°3 CD38 expression did not correlate with the presence of the B-lineage differentiation antigens CD19, CD20, CD21, and CD10. Likewise, CD71 expression was found more often in T-cell cases (92%) than in B-lineage cases (32%), and there was no correlation between CD7 1 expression and the expression of B-lineage differentiation antigens or the percentage of cells in S-phase.Io3 (Table 2) .""'" The frequency of hyperdiploidy >50 chromosomes, a favorable prognostic feature, is highest in cases of CDIO+ early pre-B ALL, whereas pseudodiploidy is present in the majority of patients with CD 10-early pre-B ALL and in virtually all cases of B-cell ALL. Cases of pre-B ALL are less likely than CDIO' early pre-B ALL to be hyperdiploid >50. T-cell ALL is characterized by a high frequency of pseudodiploidy; hyperdiploidy >50 is rare.
An increasing number of structural chromosomal abnormalities have been recognized as nonrandom changes, many ofwhich are associated with a specific immunophenotype (Table 3) ,4,'18 suggesting a relationship to leukemogenesis. Translocations, most often involving reciprocal exchanges of DNA, are the most prominent of these alterations, occumng in up to 50% of childhood ALL case^.^*'^^ Molecular analyses of breakpoint regions in leukemic lymphoblasts have identified many genes whose protein products appear to play important roles in malignant transformation and proliferation; some of the more common findings are listed in Table 3 . Continued study ofthese gene rearrangements, and their biologic effects in leukemic cells, will be critical to our understanding of specific immunophenotypes and perhaps to the formulation of new treatment strategies.
Chromosomal translocations affect TCR genes in approximately one-half of T-cell ALL casesm and involve Ig genes in virtually all B-cell ALL case^,"^,'^^ suggesting that Ig/ TCR recombinase and class-switch enzymes are mediators of interchromosomal translocation in these cases.'" B-cell ALL is invariably associated with one of three specific chromosomal translocatibns: the t(8; 14)(q24;q32.3) in approximately 80% of cases and the t(2;8)(p1 I-p12;q24) or t(8;22)(q24;q I 1) in the remainder.1'g.'20 These rearrangements consistently bring the MYC proto-oncogene on chromosome 8(q24) near the transcriptionally active gene for the Ig heavy chain on 14q32, the K light chain on 2plI-pl2, or the X light chain on 22q I 1 leading to aberrant activation of MYC.'22-'24
There is no apparent relationship between particular translocations in T-cell ALL and the level of thymocyte maturation.60 However, it is interesting that normal karyotypes are found more often in T lymphoblasts in early stages of development.60 Among childhood T-cell ALL cases, the t(l1;14)(p13;ql I ) is the most common nonrandom abnormality, occumng in 7% of patient^.'^' In virtually all cases with a t ( 1 1; 14) , the blast cells coexpress CD4 and CD8 antigen~.'~' The t( 1;14)(p32-p34;ql I ) has been recognized in 3% of T-cell ALL cases.i26 As a result of this rearrangement, the TALI gene (also known as TCLS or SCL) is markedly o v e r e~p r e s s e d . '~~~'~~ Recent studies indicate that the gene can also be activated by interstitial deletions on chromosome I without cytogenetic abnormalitie~.'~~-'~' In fact, the TALI/SCL gene, a member of the helix-loop-helix family of transcription factors, is probably the most commonly involved proto-oncogene in T-cell ALL, affecting up to 25% of pediatric case^.'^^,'^' Approximately 25% of cases of pre-B ALL have a specific chromosomal translocation, t( 1; 19)(q23;p 1 3).'32-'34 Overall, the t( 1 ; 19) is found in 5% to 6% of childhood ALL cases, making it the most common chromosomal translocation in this di~ease.~ The translocation breakpoint on chromosome 19 occurs within a single intron of the E2A gene, which encodes a transcriptional factor containing a helix-loop-helix DNA binding motif and dimerization d~main.'~'-'~' The breakpoint on chromosome lq23 interrupts a homeobox gene known as PBX1.'36*'37 As a result, chimeric transcripts with oncogenic potential are formed that fuse coding sequences of the E2A gene in frame with the PBXI sequences. Although approximately I % of early pre-B cases also have a t( 1 ; 19)-cytogenetically indistinguishable from that found in pre-B ALL"83'38-'40-they have different clinical and molecular These cases are associated with hyperdipoloidy >50 and lack of E2A-PBXI fusion protein, and have a favorable prognosis.
The Philadelphia chromosome [22q-chromosomal The order of genes (from left to right) corresponds to the order of chromosomal breakpoints in the first column.
marker resulting from the t(9;22)] and the t(4;l I ) are found in 3% to 5%'41s'42 and 2% of childhood ALL respectively. The t(9;22) fuses part of the ab1 gene on chromosome 9 with the bcr gene on chromosome 22; the resulting chimeric protein shows increased tyrosine kinase activity and is believed to play a major role in malignant transformati~n.'~~ The t(4; 1 I ) cleaves the ALL-I gene within the coding region, resulting in fusion of the open reading frames of ALL-I with the AF-4 gene on chromosome 4 in p h a~e . '~~, '~~ ALL-I encodes a putative transcription factor, whereas the function of the AF-4 protein is unclear. Both translocations are associated with an extremely poor prognosis. Although most of the Philadelphia chromosome-positive cases have an early pre-B (75%) or pre-B (16%) phenotype, T cells are involved in 9% of the cases.142 Almost all cases of the t(4;Il) are classified as CDIO-early pre-B or pre-B ALL.'43,'" Interestingly, cases with the t(9;22) or t(4;l I), in addition to those with 14q32 translocations, frequently express myeloid-associated antigens. 4, 107, 143, 148 
IMMUNOPHENOTYPIC AND CLINICAL CORRELATIONS
The distribution of specific immunophenotypes of ALL is clearly influenced by age. In infants, there is a preponderance of CD IO-early pre-B ALL and a lack of T-cell ALL (Table 4 ).L49-'53 In fact, the frequency of CDlO expression decreases with younger age among infants. In one study, CDlO expression was found in only 1 of 10 infants with early pre-B ALL who were less than 6 months of age, in 2 of I 1 between 6 to 12 months of age, and in 16 of 18 between 12 to 18 months of age.149 Likewise, the proportion ofpre-B cases with CDlO expression was lower in younger infants. Similar findings have been reported by several other Modified and reprinted with permission from Crist et al. 154 The values are weighted means from eight different studies.
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For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From groups.15@152 Myeloid-associated antigens (CD 15 and CDw65) are preferentially expressed in infant cases with the t(4;l l).143,151 T-cell ALL occurs in approximately onefourth of adolescent cases, a much higher frequency than that in younger children and infants.15G156 lmmunophenotypic subtypes of ALL also differ according to geographical and ethnic settings. Black African children have a significantly lower incidence of CD10' B-lineage ALL and a higher proportion of T-cell ALL.L57 The low incidence of ALL and the lack of an apparent age peak at 2 to 5 years in black African children are largely accounted for by this deficit of CD 10' B-lineage ALL cases. It has been postulated that an improved socioeconomic situation and hygiene with altered patterns of infection in infancy results in increased risk of CDlO+ B-lineage ALL in developed countries.157
T-cell ALL
Approximately 15% of cases of childhood ALL are classified as T-cell Male gender, older age, higher leukocyte counts, the presence of a mediastinal mass, and central nervous system (CNS) leukemia are typical features of this form of the disease (Table 5) .67"9,76,158,159,161
Children with T-cell ALL generally have a poorer prognosis than do those with early pre-B or pre-B ALL,6749,76*15s'62 although in one clinical trial of intensified chemotherapy including high-dose asparaginase and an anthracycline, the T-cell phenotype failed to show prognostic ~ignificance'~~ (Table 6 ). In a recently completed St Jude study, the 5-year event-free survival estimate (*SE) was 7 1% f 4% for all 358 patients, but was only 5 1 % k 1 1 % for the 62 T-cell patients (Fig 3) .'64 However, many of the failures were due to relapses in the CNS, most of which were successfully treated (C.-H. Pui, unpublished data).
Numerous attempts to identify subsets of T-cell cases with prognostic relevance have yielded inconsistent res u l t~.~~,~~-~~,~~,~~-~~,~~~,~~ Presenting features that we have found to be associated with an adverse prognosis in T-cell ALL include older age group (2 15 years), French-American-British (FAB) L2 morphology, abnormal leukemic cell karyotype, late thymocyte stage of differentiation (surface membrane CD3 expression), and lack of CDlO expresIn a multivariate analysis, abnormal karyotype and lack of CD 10 expression were independently associated with a poorer clinical outcome.77 The biologic basis for the adverse treatment outcome in CDlO-T-cell cases is unknown. CDlO+ and CD10-subgroups lack major differences in clinical or cytogenetic features, except that CDlO' cases are more likely to have 9p abnormalities and less likely to have CNS leukemia.77 However, the different patterns of cell surface antigen expression between CDlO+ and CD10-cases suggest biologically distinct species of T-cell ALL. Compared with CDlO-T-cell cases, the CD 1 Of cases have a high frequency of CD 1, CD4, and CD8 antigen expression, but a lower frequency of CD3 expression. Perhaps of greater interest is the finding of a high percentage of CDlO+ T-cell cases (78%) with expression of CD21,77 an antigen that serves as the receptor for C3d complement component and Epstein-Barr virus, and is expressed late in B-cell ont~geny.'~,'' Finally, in a recent study, we showed that expression of CD7 1, a T-cell activation antigen, has no prognostic significance in T-cell ALL IO3
B-Cell ALL
B-cell ALL accounts for approximately 2% of cases of childhood ALL and is usually characterized by FAB L3 cellular morphology, male sex, white race, older age at diagnosis, and extramedullary disease (eg, lymphomatous masses, CNS di~ease).'~~,'~' More than 90% of cases express cell surface Ig p heavy chains. Of these, approximately two-thirds coexpress K light chains and one-third X light chains on the cell surface.'67 Once given an extremely poor progn~sis,~.'~' patients with B-cell ALL now have a reasonable expectation of long-term survival. Cure rates of 60% to 78% have been achieved in contemporary treatment programs that feature short periods of fractionated high-dose cyclophosphamide, high-dose cytarabine and methotrexate, and intensive intrathecal chemotherapy (Fig 3 and Table 6 ).I7&l7' However, patients with CNS involvement or massive tumor burdens continue to fare p~o r l y . '~~~'~~, '~'
Pre-B ALL
The pre-B immunophenotype accounts for about onefourth of cases of newly diagnosed childhood ALL.'i4~L32~L7~i75 Leukemic cells from most patients with pre-B ALL express HLA-DR (98%) and the CDlO antigen (94%).'76 Compared with findings in early pre-B ALL, pre-B leukemia develops more often in blacks; has a larger leukemic cell burden, as reflected by higher leukocyte counts and serum lactic dehydrogenase levels; has higher hemoglobin levels; and has lower periodic acid-Schiff (PAS) score^.'^^*'^^ Pre-B lymphoblasts are also more likely to have a DNA index of less than 1.16, a pseudodiploid karyotype, and chromosomal translocations, and is less likely to be hyperdiploid >50.'32*'76 Recent studies have shown that the high-risk features formerly ascribed to pre-B ALL in general are closely associated with the presence of the t ( 1 ; 1 9) .'38, 139 Earlier trials conducted by the Pediatric Oncology Group (POG) indicated that children with pre-B ALL fare worse than those with early pre-B ALL.'75,'76 In a subsequent POG trial (ALinC 14) of antimetabolite-based intensive chemotherapy, pre-B cases without the t( 1 ; 19) had outcomes similar to results for early pre-B ALL, whereas t( 1;19)-positive pre-B cases fared worse (Table 6 ).'39 An unfavorable prognosis for pre-B cases with the t( 1;19) was also noted in St Jude Total Therapy Study X, although in Study XI, which tested a much more intensive regimen, patients with the t(1;19) had essentially the same outcome as those without this rearrangement (Table 6) .'38 In a recent update of these results, the estimated 5-year event-free survival (+SE) for the t(1;19) cases was 80% f 21%.'@ Although this finding should be viewed as preliminary owing to the relatively small number of cases studied, it supports the contention that effective therapy can override the influence of adverse biologic risk factors. A recent study of the clinical significance of two forms of the t( 1 ; 19) in pre-B ALL suggested that the balanced form was associated with a poorer prognosis than the unbalanced translocation [der( 19)t( 1 ; 1 9)],'77 a finding that requires confirmation.
Early Pre-B ALL

Most cases of ALL (~6 0 % )
involve the early pre-B phenotype. HLA-DR and CD19 antigens are present on lympho- use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From blasts in virtually all of these cases. Although, collectively, early pre-B cases are more likely to have favorable presenting features (eg, age range of 1 to 9 years and low leukocyte C O U~~S ) ,~,~~,~~,~~,~~~,~~~ they constitute a variety of subgroups with diverse clinical and biologic features and outcome.
Many higher-risk features within the early pre-B subgroup (eg, hyperleukocytosis, leukemic cell DNA index < 1.16, or pseudodiploidy) are related to the absence of the CD 10 marker, a feature common to infants.67-70274 In at least two s t~d i e s ,~~,~~ CD 10 expression lost its prognostic impact when infants were excluded from analysis. Thus, the poor prognosis of CD IO-B-lineage ALL appears confined to infant cases.
The clinical relevance of CD34 expression was recently assessed in a POG This marker was detected more often in early pre-B than in pre-B cases (79% v 6 1 %), and its presence was associated with hyperdiploidy >50, a lower frequency of initial CNS leukemia, and a favorable prognosis. We have recently confirmed the relationship between this marker and favorable presenting features and outcome in B-lineage ALL.'78 CD24 is acquired during early developmental stage of B-cell ontogeny. The lack of this antigen expression in leukemic cells corresponds to a very early stage of B-lineage ALL.I5 Interestingly, a recent study showed that the lack of CD24 expression was associated with intrinsic radiation resistance at the level of primary clonogenic b 1 a~t s . I~~ Three additional antigens-CD45, CD38, and CD7 1-do not appear to convey clinically useful information in cases of early pre-B ALL.93,Lo3 CD45 was expressed in 84% of early pre-B and 8 1 ?h of pre-B cases. Cases lacking CD45 had significantly lower leukocyte counts and lower serum lactic dehydrogenase levels and were more likely to have leukemic cell hyperdiploidy >50 or a DNA index 2 1.1 693-all favorable presenting features in this Interestingly, there was an inverse linear correlation between CD45 expression and the DNA index, suggesting that the cellular cytoskeletal proteins that anchor the CD45 antigen'" are related to orderly cell mitosis. However, although clinical outcome clearly worsened as the level of CD45 expression increased in these cases, the prognostic impact lessened substantially after adjustment for DNA index. Similarly, the activation antigens CD38 and CD7 1 lacked prognostic significance in a recent study.103
Transitional Pre-B ALL
A small subset of children ( N I %) with ALL was recently found to have blasts that express cytoplasmic and surface p heavy chains but not Ig light chains, indicating that these cells are in transition between the pre-B and B stages of differentiati~n."~ These cases were termed transitional pre-B ALL because their blasts lacked the cytoplasmic or surface light chains that typically characterize normal B cells. They also lacked FAB L3 morphology or the chromosomal translocations associated with B-cell ALL, and had lower leukocyte counts as well as a higher prevalence of DNA indexes 2 1.16 than did cases of pre-B ALL. Identification of patients with transitional pre-B ALL is important because, unlike patients with B-cell ALL, they have an excellent clinical outcome when treated with antimetabolite-based chemotherapy. Transitional pre-B cells have also been identified at low frequency in normal bone m a r r o~,~~~-'~~ indicating that surface marker expression of heavy chains does not require light chain production.
MIXED-LINEAGE ANTIGEN EXPRESSION
Since the early 198Os, it has been recognized that leukemic blast cells can coexpress antigens associated with more than one lineage.'06.'07.'4s*'8"207 This lineage heterogeneity has been variously explained as a reflection of aberrant gene expression, malignant transformation of pluripotent progenitor cells, or immortalization of rare progenitor cells coexpressing features of more than one lineage.106.'84 Numerous terms have been used to describe these cases, but standard nomenclature is l a~k i n g . '~~~'~~ Recently, rare subpopulations of normal marrow B-lymphoid cells were found to express "asynchronous" immunophenotypes characteristic of some B-lineage ALL cases3' Moreover, the CD2 molecule was also found on normal human B-lymphoid progenitors.208 Together, these findings suggest that some progenitor cells may evolve through a period of mosaic gene expression, during which the cells may be prone to leukemic transformation. Malignant transformation of these progenitor cells could result in "mixed-lineage" leukemia.
With the use of more comprehensive panels of MoAbs in immunophenotyping, increasing numbers of cases are being characterized as having "mixed-lineage" expression. Myeloid-associated antigen expression has been reported in up lymphoid-associated antigen expression in up to 60% of childhood acute myeloid leukemia (AML).'07,L86,2052206 In some cases of ALL, leukemic blasts coexpressed both T-and B-lineage-associated antigens (eg, CD2+/CD 19+ or CD7+/ CD 1 9+).15,207*209 Leukemic blasts coexpressing T-, B-, and myeloid-associated antigens have also been reported ( Fig   As mentioned earlier , none of the surface antigens studied to date are lineage-specific. For example, CD2, the E-rosette receptor, is expressed in almost one-half of the cases of acute promyelocytic especially in the microgranular variant.'" CD4, another T-associated marker, is expressed in two-thirds of cases of M4 or M5 leukemia205,21'; CD 19, a B-lineage-associated antigen, can be found on blast cells of three-fourths of cases of AML with the t(8;21)2L3,2L4; whereas CD15 is expressed in two-thirds of ALL cases with the t(4;l 1).'43J44 Thus, more stringent criteria (ie, expression of two or more markers of another lineage) must be applied in the diagnosis of mixed-lineage cases.'07
Clinically, these cases can be subdivided into lymphoid antigen-positive (Lyf) AML or myeloid antigen-positive (My+) ALL.'07 The Ly+ AML cases are characterized by FAB M 1 or M2 morphology, low levels of myeloperoxidase reactivity, and combined populations of myeloperoxidasepositive large blasts and small blasts, generally of handmirror morphology. 107~188~199 Importantly, some of these patients may respond to lymphoid-directed therapy (prednisone, vincristine, and L-asparaginase) after failing to respond on protocols for myeloid l e~k e m i a . The prognostic significance of myeloid-associated antigen expression in childhood ALL remains uncertain. Although some studies have shown that expression of myeloid-associated antigens is a predictor of a poor outcome:00.20' we and others were unable to confirm this result (Table 6 ).203*204 In our study, the estimated 3-year event-free survival (?SE) was 85% ? 6% for 50 patients with My+ ALL, as compared with 75% f 3% for the remaining 260 patients.203 The reason for the difference in treatment outcome for My+ ALL in these studies is not entirely clear.
We suggest that the prognostic importance of myeloid antigen expression, like most other clinical and laboratory features, is treatment dependent and can be abolished with highly effective therapy.
TREATMENT PLANNING BY IMMUNOPHENOTYPE
Despite recent improvements in leukemia therapy, the immunologic subtypes of ALL still warrant consideration of different approaches to treatment. For instance. the density of glucocorticoid receptors in blast cells differs among the recognized phenotypes, in the descending order ofearly pre-B > pre-B > T-cell > B-cell ALL.2'5*2'6 Although a high number of receptors does not guarantee a response to corticosteroids, leukemic cells with few receptors, such as B cells, usually respond poorly to these agent^.^" Moreover, cyclophosphamide appears to be more effective for B-cell and perhaps T-cell ALL than for the pre-B and early pre-B subclasses. In fact. single-agent cyclophosphamide therapy has been curative in some patients with advanced B-cell malignancy.2'8 In mice, T-cell leukemia was shown to be more sensitive to cyclophosphamide and cytarabine than to methotrexate and mer~aptopurine.~'~ A comparative clinical trial showed that a cyclophosphamide-cytarabine combination could improve disease-free survival for children with T-cell ALL, but not for those with non-T-cell disease. 220 The difference in cellular proliferative rates (B-cell> T-cell > early pre-B ALL)"' has also been used in planning treatment protocols, especially for B-cell and T-cell ALL.
Currently, the POG is the only major treatment group use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From that maintains separate treatment protocols for T-cell, Bcell, and other B-lineage (early pre-B and pre-B) ALLS. The justification for this approach lies in the need to ensure a level of treatment intensity appropriate for the patient's risk category. For instance, by using antimetabolite-based therapy without cranial irradiation for the majority of children with B-progenitor ALL,162 POG investigators showed the feasibility of omitting highly toxic agents in regimens for a large subgroup of ALL patients. Organizing clinical trials on the basis of immunophenotype therefore provides an efficient way to assess the toxicityfefficacy ratio of treatment intensification or reduction.
Recent improvements in assays of in vitro drug sensitivity may allow discrimination of cellular drug resistance profiles according to the biologic subtype of leukemia. In this regard, Pieters et a1222 found that blast cells from cases of Tcell, B-cell, and CDlO-early pre-B-cell ALL were more resistant to prednisolone, daunorubicin, and L-asparaginase, according to the MTT (3-[4,5-dimethylthiazol-2-y1]-2,Sdiphenyl tetrazolium bromide) assay.
Finally, there is evidence to suggest that MoAb therapy directed to specific differentiation antigens might be useful in destroying leukemic cells. Since its first use in 1979,223 well over 100 patients with a variety of hematologic malignancies have been treated by this method224; however, numerous obstacles to serotherapy have been recognized, including antigen shedding, antigen modulation, nonspecific binding, heterogeneity of antigen expression, low cytotoxicity, and increased systemic Although occasional complete responses have been r e p~r t e d ,~~' .~~~ the results of clinical trials using unconjugated MoAbs as serotherapy have been largely disappointing. A more promising avenue has been the use of antibody-toxin conjugates (immunotoxins). In preliminary trials, these compounds have induced complete responses while causing several prominent side effects, most often capillary leak ~y n d r o m e ?~~-~~~ There is also evidence of synergy between immunotoxins and chem~t h e r a p y ,~~' a combination that remains to be exploited clinically. Finally, MoAbs have been used to purge leukemic cells from harvested bone marrow before its reinfusion into patients undergoing autologous bone marrow transplantation Only 2% to 4% of adults have a B-cell p h e n~t y p e .~~~,~~~,~~~ B ecause cIg is not routinely assayed in adult series, the frequency of the pre-B immunophenotype in this age group is unknown. As in childhood cases, T-cell ALL in adults is characterized by male predominence, high leukocyte count, an increased frequency of anterior mediastinal mass, and CDlO positivity in approximately 40% of Adult CD 10-B-lineage ALL has been associated with a poor prognosis, whereas several investigators reported a relatively favorable prognosis for adult T-cell ALL, using cytarabine in combination with either cyclophosphamide or teniposide.234,236,237,240 Little is known about prognostic factors in individual immunophenotypic subtypes of adult ALL. In one study, a high leukocyte count conferred a poor prognosis in B-lineage ALL but not in T-cell cases.24o
My+ ALL appears to be more common in adults than in children. In six combined series of adult ALL cases, 113 (33.3%) of 339 patients had lymphoblasts that expressed one or more myeloid Even when more stringent criteria were used, the diagnosis of My+ ALL could be made in up to 18% of a d~l t s ,~~'~'~~ in contrast to 6% to 8% of ~h i l d r e n . ' '~,~~ An increased frequency of L2 morphology, azurophilic cytoplasmic granules, acid a-naphthyl acetate esterase positivity, and unusual morphology (monocytoid features and cytoplasmic buds) has been observed for blast cells of My+ ALL cases in adult^.'^^,'^^ In most adult series, My+ ALL was associated with a lower remission induction rate and shorter survival
DETECTION OF MINIMAL RESIDUAL LEUKEMIA
Conventional methods for detecting residual leukemia, such as cell morphologic,242
and Southern analyses, have sensitivities between 1% and 5%. Gene amplification by the polymerase chain reaction (PCR) offers greater sensitivity than do other available methods.248-257 Nonetheless, all PCR methods have limitations, including amplification of genome segments from nonviable or nondividing leukemic cells. The doublemarker immunofluorescence assay is another sensitive alternative for detecting minimal residual leukemia at levels below 1 0-4 malignant ce11s.255,258-260 Th' is method is based on the premise that certain combinations of differentiation antigens are expressed on leukemic blasts or normal cells confined to extramedullary sites (eg, thymus), but are absent from normal peripheral blood and bone marrow. But this method can be applied only to the 30% to 40% of ALL cases with phenotypic features that are extremely rare or absent in normal bone marrow. Thus, all approaches to the detection of minimal residual leukemia carry certain limitations and specific advantages, and should be viewed as complementary to each other. Although the clinical utility of routine screening for residual ALL remains to be determined in prospective trials, the expectation is that early detection of residual leukemia will permit beneficial treatment modifications before relapse.
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SUMMARY
Immunologic marker studies of the lymphoid leukemias have greatly improved the precision of diagnosis of these disorders by providing specific information regarding the lineage and stage of maturation of the malignant cells. Such studies have also enhanced our understanding of normal lymphocyte development, permitting reproducible identification of lymphoid cells in discrete developmental stages. By elucidating the functions of lymphoid cell differentiation antigens, it has been possible to gain insight into the signal transduction mechanisms by which these cells interact among themselves and with other cell types. Similar studies use only. 
